Photo of Jann N Sarkaria

View Scopus Profile

Jann N Sarkaria, MD

  • 14230 Citations
  • 54 Scopus h-Index
1993 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Comment/debate
2019

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

Jaeckle, K. A., Anderson, S. K., Twohy, E. L., Dixon, J. G., Giannini, C., Jenkins, R. B., Egorin, M. J., Sarkaria, J. N., Brown, P. D., Flynn, P. J., Schwerkoske, J., Buckner, J. C. & Galanis, E., Jul 1 2019, In : Journal of neuro-oncology. 143, 3, 1 p.

Research output: Contribution to journal › Comment/debate

Open Access
2012

Erratum: Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients (Journal of Clinical Investigation (2012) 122, 1, (253-266) DOI: 10.1172/JCI59334)

Agnihotri, S., Gajadhar, A. S., Ternamian, C., Gorlia, T., Diefes, K. L., Mischel, P. S., Kelly, J., McGown, G., Thorncroft, M., Carlson, B. L., Sarkaria, J. N., Margison, G. P., Aldape, K., Hawkins, C., Hegi, M. & Guha, A., Feb 2012, In : Journal of Clinical Investigation. 122, 2, 1 p.

Research output: Contribution to journal › Comment/debate